Pharmaceutical giants are navigating a complex landscape of fluctuating demand and regulatory hurdles, impacting their financial performance and strategic outlook. Merck & Co. Inc. (NYSE:MRK) is the latest to face these challenges, as its recent earnings report reveals a mixed bag of successes and setbacks.
Merck reported a mixed second-quarter earnings picture on Tuesday. Adjusted earnings exceeded analyst consensus, but overall sales declined slightly year-over-year and fell short of revenue expectations.
- MRK is consolidating close to its 52-week bottom. See real-time price here.
Investors were concerned about a significant drop in Gardasil vaccine sales, even as its blockbuster cancer drug Keytruda continued its strong growth trajectory.
Adjusted earnings per share of $2.13 surpassed consensus estimates of $2.04, marking a decline …